Eventide Asset Management - BRIDGEBIO PHARMA INC ownership

BRIDGEBIO PHARMA INC's ticker is BBIO and the CUSIP is 10806X102. A total of 205 filers reported holding BRIDGEBIO PHARMA INC in Q1 2021. The put-call ratio across all filers is 1.92 and the average weighting 0.8%.

Quarter-by-quarter ownership
Eventide Asset Management ownership history of BRIDGEBIO PHARMA INC
ValueSharesWeighting
Q3 2023$18,905,365
+16.8%
716,927
-23.8%
0.34%
+24.1%
Q2 2023$16,188,227
+3.7%
941,1760.0%0.27%
-4.2%
Q1 2023$15,604,698
-64.1%
941,176
+32.2%
0.29%
-50.9%
Q2 2021$43,416,000
-1.0%
712,1970.0%0.58%
-10.3%
Q1 2021$43,871,000712,1970.65%
Other shareholders
BRIDGEBIO PHARMA INC shareholders Q1 2021
NameSharesValueWeighting ↓
Aisling Capital Management LP 6,068,125$160,016,45665.94%
Kohlberg Kravis Roberts & Co. L.P. 31,060,971$819,077,80528.79%
Cormorant Asset Management, LP 4,662,530$122,950,9167.17%
Frazier Life Sciences Management, L.P. 2,725,949$71,883,2754.77%
Octagon Capital Advisors LP 971,639$25,622,1203.94%
M28 Capital Management LP 121,200$3,196,0443.66%
VIKING GLOBAL INVESTORS LP 25,120,991$662,440,5332.69%
BOONE CAPITAL MANAGEMENT LLC 313,381$8,263,8572.61%
Fernwood Investment Management, LLC 235,620$6,213,2992.23%
SOUTHPORT MANAGEMENT, L.L.C. 15,000$395,5502.15%
View complete list of BRIDGEBIO PHARMA INC shareholders